Boogers Lidewij Sophia, Sikma Boukje Teatske, Bouman Mark-Bram, van Trotsenburg Adrianus Sarinus Paulus, den Heijer Martin, Wiepjes Chantal Maria, Hannema Sabine Elisabeth
Center of Expertise on Gender Dysphoria, Amsterdam UMC location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, 1081 HV Amsterdam, The Netherlands.
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1411-e1419. doi: 10.1210/clinem/dgae574.
Skeletal dimensions vary between sexes. Men typically have broader shoulders and women a wider pelvis. Whether gender-affirming hormone therapy (GAHT) with or without prior puberty suppression (PS) alters these dimensions in transgender individuals remains unclear.
To investigate impact of PS and GAHT on skeletal dimensions.
This retrospective cross-sectional study, conducted at a gender identity clinic, included transgender individuals assigned male at birth (AMAB) and assigned female at birth (AFAB) who underwent dual-energy x-ray absorptiometry (DXA) scanning between ages 18 and 28 years and who were divided into 4 groups: Early PS (Tanner G/B2-3) + GAHT, Late PS (Tanner G/B4-5) + GAHT, GAHT-only, and untreated. Shoulder and pelvis dimensions measured by DXA were compared between groups, with adjustment for height.
A total of 121 individuals AMAB and 122 AFAB were included. Only individuals AMAB who underwent early PS had smaller shoulders compared to untreated individuals AMAB (-1.3 cm; 95% CI -2.1; -0.5). In individuals AMAB from both the Early and Late PS groups, pelvic inlet, pubic symphysis width, and interischial distance were greater compared to untreated individuals AMAB, resulting in dimensions comparable to untreated individuals AFAB. Only in Early PS AFAB was pelvic inlet width smaller compared to untreated individuals AFAB (-1.0 cm; 95% CI -1.5; -0.6), and comparable to untreated individuals AMAB.
The study results suggest that skeletal dimensions are only altered by GAHT if endogenous puberty has not yet been completed at start of PS. These findings enhance our understanding of hormonal effects on the skeleton and may hold clinical relevance for body image as well as for forensic anthropology. Future research should evaluate clinical implications for surgical or obstetrical outcomes in transgender individuals.
骨骼尺寸存在性别差异。男性通常肩部更宽,女性骨盆更宽。对于接受或未接受过青春期抑制(PS)的跨性别者,性别确认激素疗法(GAHT)是否会改变这些尺寸尚不清楚。
研究PS和GAHT对骨骼尺寸的影响。
这项在性别认同诊所进行的回顾性横断面研究纳入了出生时被指定为男性(AMAB)和出生时被指定为女性(AFAB)的跨性别者,他们在18至28岁之间接受了双能X线吸收法(DXA)扫描,并被分为4组:早期PS(坦纳G/B2 - 3)+ GAHT、晚期PS(坦纳G/B4 - 5)+ GAHT、仅GAHT组和未治疗组。对各组通过DXA测量的肩部和骨盆尺寸进行比较,并对身高进行校正。
共纳入121名AMAB个体和122名AFAB个体。与未治疗的AMAB个体相比,只有接受早期PS的AMAB个体肩部较小(-1.3厘米;95%可信区间-2.1;-0.5)。在早期和晚期PS组的AMAB个体中,与未治疗的AMAB个体相比,骨盆入口、耻骨联合宽度和坐骨间距离更大,导致尺寸与未治疗的AFAB个体相当。只有在早期PS的AFAB个体中,骨盆入口宽度比未治疗的AFAB个体小(-1.0厘米;95%可信区间-1.5;-0.6),且与未治疗的AMAB个体相当。
研究结果表明,只有在PS开始时内源性青春期尚未完成的情况下,GAHT才会改变骨骼尺寸。这些发现增进了我们对激素对骨骼影响的理解,可能对身体形象以及法医人类学具有临床意义。未来的研究应评估对跨性别者手术或产科结局的临床影响。